Published in Alzheimers Res Ther on December 02, 2011
Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Sci Rep (2015) 0.89
Astrocytosis measured by ¹¹C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. Eur J Nucl Med Mol Imaging (2014) 0.86
Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A (2015) 0.83
New treatment strategies for Alzheimer's disease: is there a hope? Indian J Med Res (2013) 0.82
Serum metabolomic biomarkers of dementia. Dement Geriatr Cogn Dis Extra (2014) 0.82
Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci (2013) 0.79
Neuroimaging of dementia in 2013: what radiologists need to know. Eur Radiol (2013) 0.79
Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by (3)H-THK5117 and (3)H-deprenyl autoradiography. Sci Rep (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Pathways towards and away from Alzheimer's disease. Nature (2004) 8.72
Cognitive reserve. Neuropsychologia (2009) 8.41
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 5.42
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Alzheimer's disease: clinical trials and drug development. Lancet Neurol (2010) 4.65
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology (2004) 4.00
Systemic inflammation and disease progression in Alzheimer disease. Neurology (2009) 3.79
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology (2003) 3.62
In-vivo measurement of activated microglia in dementia. Lancet (2001) 3.51
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol (2004) 3.39
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry (2002) 2.80
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology (2009) 2.27
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis (2008) 2.27
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci (2005) 2.17
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry (2008) 2.06
Biomarkers in Alzheimer's disease drug development. Alzheimers Dement (2011) 1.97
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med (2009) 1.77
Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology (2009) 1.70
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol (2011) 1.67
PET imaging of amyloid in Alzheimer's disease. Lancet Neurol (2004) 1.55
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
PET amyloid ligand [11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord (2008) 1.39
Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol (2011) 1.32
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging (2010) 1.24
High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr Alzheimer Res (2010) 1.23
Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. J Neurochem (2009) 1.21
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med (2012) 1.19
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
Amyloid imaging in Alzheimer's disease. Curr Opin Neurol (2007) 1.14
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int (2008) 1.11
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging (2011) 1.09
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord (2010) 1.04
Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging (2008) 0.96
Activated astrocytes: a therapeutic target in Alzheimer's disease? Expert Rev Neurother (2009) 0.94
Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res Ther (2011) 0.93
Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging (2002) 0.92
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging (2006) 0.91
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) (2007) 0.88
Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J Alzheimers Dis (2011) 0.86
Nicotinic acetylcholine receptor interaction with beta-amyloid: molecular, cellular, and physiological consequences. Curr Alzheimer Res (2010) 0.85
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging (2007) 0.83